Australia's Surgical Surcharge
Report

Australia's Surgical Surcharge

clock

16.06.2023 - 07:17

HealthEconomics

Mandala's report commissioned by Private Healthcare Australia unpacks how Australians are paying too much for medical devices through the Prescribed List of Medical Devices (PL).

Australia pays some of the highest prices in the world for medical devices through the Prescribed List of Medical Devices (PL).


Australia’s spending on medical devices through the PL since 2006 has grown three times faster than inflation. Prices of medical devices on the PL are much higher in Australia compared to an aggregate of eight peer countries, including the United Kingdom, New Zealand, and France.


Australia pays 70 per cent more through the PL than New Zealand for a hip replacement stem, for example, and 30 per cent more for a drug eluting stent.

portableText image


Australia pays two to four times more than peers abroad for a selection of frequently-used devices.


The cost for a selection of 46 frequently-used devices is twice as much in Australia compared to the average of these eight overseas markets. Compared to the lowest prices from these markets, prices on Australia’s PL are four times higher.


Germany pays the least for these 46 devices: just a quarter of what Australia does through the PL.


These high prices persist despite the fact that the medical device market is mature with a diverse range of suppliers. Instead, the PL’s lack of bundling and price adjustment mechanisms to consider cost effectiveness, international benchmarking, and other settings to boost competition have seen costs grow.

portableText image


Consumers foot the bill. The total cost of medical devices on the PL is an estimated $967 million higher than in similar countries per year. This is a direct value transfer to device companies, most of whom are based overseas.


$619 million of these additional costs are paid by consumers through their private health insurance premiums, $77 million paid by consumers through self-insurance, and $271 million paid by the federal government through the Private Health Insurance Rebate, veterans’ care, and workers’ compensation.


The government must also fund the administration of the PL, despite the fact that this centrally-managed system does not result in lower costs and isolates prices from the downward pressure of market forces. This is estimated at approximately $14 million per year.

Rising costs that contribute to premium growth leads to lower participation in private health insurance, especially when cost-of-living pressures are high. In turn, lower insurance participation mean that a larger share of Australians must rely on the public system.
Higher premiums also reduce consumer spending and are an additional drag on other sectors of the economy.

portableText image


There is an opportunity to further reform the pricing framework of medical devices in Australia to lower prices and boost patient outcomes by embracing a more open and competitive system.


An ageing population will mean demand for medical devices will keep growing. Ensuring prices are sustainable in the long term while prioritising patient outcomes is a critical challenge facing Australian healthcare.
Aligning prices to those abroad is unlikely to impact supply or require co-payments. Countries such as Germany, Sweden, and Austria pay a quarter of Australia’s prices and still enjoy plentiful supply, without charging patients co-payments.


Australia’s relatively small market size and distant geography should not be a barrier to lower prices. New Zealand’s prices are 1.7 times lower.

There are greater opportunities to better align price signals with clinical effectiveness through a reformed PL. As an example, our hip and knee replacement revision rates through the PL are 3 percentage points higher compared to in the United Kingdom, New Zealand, and Sweden.

Read the full report here.

Read our latest posts

Building Australia’s AI capability
AIWorkforceProductivity

Building Australia’s AI capability

The AI shift promises significant economic gains for Australia, but these gains will only be realised and shared throughout the economy if we invest in our human capital as well as our physical capital. Investment to date has focused on infrastructure, particularly data centres, but the workforce likewise requires investment to ensure we have the skills required to harness AI’s full potential. An estimated $17.3B in AI skills investment is required over the next five years to ensure Australia can exceed the frontier, develop mature national capability, and unlock new long-term sources of growth.

16 Nov, 2026

Reimagining the value of the arts – An introduction to the Economist in Residence Platform
Pro-bonoThe Arts

Reimagining the value of the arts – An introduction to the Economist in Residence Platform

Reimagining the value of the arts introduces the Economist in Residence platform, a collaboration between RISING and Mandala. Australians are attending the arts in record numbers, yet public investment per person has fallen and artists and venues are under pressure. The report argues that current valuation methods miss the health, social and strategic benefits of the arts, which weakens the case for funding. It proposes a different question: not what the arts are worth, but how they help Australia meet shared national goals. Over the next year, the platform will build the evidence base across three pillars: cultural good, economic sector and strategic asset.

12 Nov, 2026

Harnessing AI in the court system
AITechnologyLegal services

Harnessing AI in the court system

Mandala’s latest research, commissioned by Microsoft, examines how AI can help Australian courts improve access to justice by reducing persistent case backlogs. We find that three promising AI applications (smart scheduling, document review and legal research support) could deliver around 95,500 additional case finalisations a year. These applications help courts manage existing workloads more efficiently, while reinforcing the integrity of court processes.

29 Oct, 2026

Rethinking the APR
EconomicsFinTechFinancial servicesGovernment

Rethinking the APR

Mandala's latest research, commissioned by Block, examines whether US credit disclosure requirements remain fit for purpose in a rapidly evolving lending market. Drawing on economic analysis, a survey of nearly 1,600 US consumers and small business decision-makers, and proprietary credit data, the report finds that Annual Percentage Rate (APR) disclosures can misrepresent the perceived cost of short-term borrowing and influence consumer choices. The report makes the case for modernising credit disclosure requirements, with a more flexible approach that better reflects different credit products while preserving consumer protection and access to credit.

15 Oct, 2026

Loading...